广州银诺医药集团股份有限公司（「银诺医药-B」，股份代号：02591）于2026年3月4日发布截至2026年2月28日的证券变动月报表。报告显示，公司本月无新增股份发行或回购行为，股本结构保持稳定。
公司注册资本合计为人民币456,819,349元，分为420,285,370股于香港联交所上市的H股，以及36,533,979股未上市股份。报告期内，两类股份数量均无新增或减少，分别维持在420,285,370股和36,533,979股，总股本不变。
公司同时确认已符合香港联交所关于最低公众持股量的要求。公司声明将持续遵守香港联交所《上市规则》及相关法律规定。根据公告信息，本次月报由联席公司秘书杨东妍签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.